Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Tuesday that its Phase III lidERA trial of giredestrant met its primary endpoint in early-stage ER-positive, HER2-negative breast cancer.

At interim analysis, giredestrant showed a statistically significant and clinically meaningful improvement in invasive disease-free survival compared with standard endocrine therapy.

According to Genentech, this marks the first time an oral selective estrogen receptor degrader (SERD) has demonstrated such a benefit in the adjuvant setting. Overall survival data remain immature, but a positive trend was observed, and the treatment was well tolerated with no unexpected safety issues.

This is the second positive Phase III trial for giredestrant following the evERA results presented at ESMO 2025.

Genentech plans to present the data at an upcoming medical meeting and share findings globally with regulatory authorities.